<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34788013</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4995</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>48</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>Trichostatin A Relieves Growth Suppression and Restores Histone Acetylation at Specific Sites in a FUS ALS/FTD Yeast Model.</ArticleTitle><Pagination><StartPage>3671</StartPage><EndPage>3675</EndPage><MedlinePgn>3671-3675</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.biochem.1c00455</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that often occurs concurrently with frontotemporal dementia (FTD), another disorder involving progressive neuronal loss. ALS and FTD form a neurodegenerative continuum and share pathological and genetic features. Mutations in a multitude of genes have been linked to ALS/FTD, including <i>FUS.</i> The FUS protein aggregates and forms inclusions within affected neurons. However, the precise mechanisms connecting protein aggregation to neurotoxicity remain under intense investigation. Recent evidence points to the contribution of epigenetics to ALS/FTD. A main epigenetic mechanism involves the post-translational modification (PTM) of histone proteins. We have previously characterized the histone PTM landscape in a FUS ALS/FTD yeast model, finding a decreased level of acetylation on lysine residues 14 and 56 of histone H3. Here, we describe the first report of amelioration of disease phenotypes by controlling histone acetylation on specific modification sites. We show that inhibiting histone deacetylases, via treatment with trichostatin A, suppresses the toxicity associated with FUS overexpression in yeast by preserving the levels of H3K56ac and H3K14ac without affecting the expression or aggregation of FUS. Our data raise the novel hypothesis that the toxic effect of protein aggregation in neurodegeneration is related to its association with altered histone marks. Altogether, we demonstrate the ability to counter the repercussions of protein aggregation on cell survival by preventing specific histone modification changes. Our findings launch a novel mechanistic framework that will enable alternative therapeutic approaches for ALS/FTD and other neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Seth A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Brooklyn College, Brooklyn, New York 11210, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ph.D. Program in Biochemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobos</LastName><ForeName>Samantha N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Brooklyn College, Brooklyn, New York 11210, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirzakandova</LastName><ForeName>Melagras</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Brooklyn College, Brooklyn, New York 11210, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallah</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Brooklyn College, Brooklyn, New York 11210, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Elizaveta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Brooklyn College, Brooklyn, New York 11210, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelakakis</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Brooklyn College, Brooklyn, New York 11210, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rana</LastName><ForeName>Navin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Brooklyn College, Brooklyn, New York 11210, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hugais</LastName><ForeName>Muna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Brooklyn College, Brooklyn, New York 11210, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrente</LastName><ForeName>Mariana P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0001-8220-2228</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Brooklyn College, Brooklyn, New York 11210, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ph.D. Program in Biochemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K22 NS091314</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>3X2S926L3Z</RegistryNumber><NameOfSubstance UI="C012589">trichostatin A</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042421" MajorTopicYN="N">Histone Code</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006877" MajorTopicYN="N">Hydroxamic Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>17</Day><Hour>17</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34788013</ArticleId><ArticleId IdType="mid">NIHMS1881080</ArticleId><ArticleId IdType="pmc">PMC10041660</ArticleId><ArticleId IdType="doi">10.1021/acs.biochem.1c00455</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, and Chinea A (2015) A comprehensive review of amyotrophic lateral sclerosis, Surgical Neurology International 6, 171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan M, Talbot K, and Ansorge O (2016) Pathogenesis of FUS-associated ALS and FTD: insights from rodent models, Acta Neuropathologica Communications 4, 99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5011941</ArticleId><ArticleId IdType="pubmed">27600654</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y, and Huang EJ (2016) Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis, Brain Research 1647, 65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003642</ArticleId><ArticleId IdType="pubmed">27033831</ArticleId></ArticleIdList></Reference><Reference><Citation>Allis CD, and Jenuwein T (2016) The molecular hallmarks of epigenetic control, Nature Reviews Genetics 17, 487.</Citation><ArticleIdList><ArticleId IdType="pubmed">27346641</ArticleId></ArticleIdList></Reference><Reference><Citation>Luger K, and Mader AW (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. (Cover story), Nature 389, 251.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305837</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzio EA, and Soliman KF (2012) Basic concepts of epigenetics: impact of environmental signals on gene expression, Epigenetics 7, 119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3335905</ArticleId><ArticleId IdType="pubmed">22395460</ArticleId></ArticleIdList></Reference><Reference><Citation>Strahl BD, and Allis CD (2000) The language of covalent histone modifications, Nature 403, 41&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">10638745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett SA, Tanaz R, Cobos SN, and Torrente MP (2019) Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease, Translational Research 204, 19&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331271</ArticleId><ArticleId IdType="pubmed">30391475</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcoran LJ, Mitchison TJ, and Liu Q (2004) A Novel Action of Histone Deacetylase Inhibitors in a Protein Aggresome Disease Model, Current Biology 14, 488&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">15043813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna S, Esposito S, Masala A, Sini P, Nieddu G, Galioto M, Fais M, Iaccarino C, Cestra G, and Crosio C (2020) HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo, Cell Death &amp; Disease 11, 369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224392</ArticleId><ArticleId IdType="pubmed">32409664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH Jr., and Ferrante RJ (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice, J Neurochem 93, 1087&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">15934930</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo Y-E, and Ko C-P (2011) Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis, Experimental Neurology 231, 147&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">21712032</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, and Gitler AD (2011) Molecular Determinants and Genetic Modifiers of Aggregation and Toxicity for the ALS Disease Protein FUS/TLS, PLoS biology 9, e1000614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082519</ArticleId><ArticleId IdType="pubmed">21541367</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Bennett SA, Rana N, Yousuf H, Said M, Taaseen S, Mendo N, Meltser SM, and Torrente MP (2018) Neurodegenerative Disease Proteinopathies Are Connected to Distinct Histone Post-translational Modification Landscapes, ACS Chem Neurosci 9, 838&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5906139</ArticleId><ArticleId IdType="pubmed">29243911</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JA, Kim YE, Seok HJ, Park WY, Kwon HJ, and Lee Y (2011) Differentiation and upregulation of heat shock protein 70 induced by a subset of histone deacetylase inhibitors in mouse and human embryonic stem cells, BMB Rep 44, 176&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">21429295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuta R, Larochelle N, Fernandez M, Pal A, Minotti S, Tibshirani M, St. Louis K, Gentil BJ, Nalbantoglu JN, Hermann A, and Durham HD (2020) Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models, Cell Stress and Chaperones 25, 173&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985055</ArticleId><ArticleId IdType="pubmed">31900865</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, McCaffery JM, Lindquist S, and Gitler AD (2008) A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity, Proc Natl Acad Sci U S A 105, 6439&#x2013;6444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2359814</ArticleId><ArticleId IdType="pubmed">18434538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinohe M, Hanaoka F, and Masumoto H (2011) Hst3 and Hst4 histone deacetylases regulate replicative lifespan by preventing genome instability in Saccharomyces cerevisiae, Genes to Cells 16, 467&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">21401809</ArticleId></ArticleIdList></Reference><Reference><Citation>Workman JJ, Chen H, and Laribee RN (2016) &amp;lt;em&amp;gt;Saccharomyces cerevisiae&amp;lt;/em&amp;gt; TORC1 Controls Histone Acetylation by Signaling Through the Sit4/PP6 Phosphatase to Regulate Sirtuin Deacetylase Nuclear Accumulation, Genetics 203, 1733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4981274</ArticleId><ArticleId IdType="pubmed">27343235</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillingham J, Recht J, Silva AC, Suter B, Emili A, Stagljar I, Krogan NJ, Allis CD, Keogh M-C, and Greenblatt JF (2008) Chaperone Control of the Activity and Specificity of the Histone H3 Acetyltransferase Rtt109, Molecular and Cellular Biology 28, 4342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447148</ArticleId><ArticleId IdType="pubmed">18458063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cote JM, Kuo Y-M, Henry RA, Scherman H, Krzizike DD, and Andrews AJ (2019) Two factor authentication: Asf1 mediates crosstalk between H3 K14 and K56 acetylation, Nucleic acids research 47, 7380&#x2013;7391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6698667</ArticleId><ArticleId IdType="pubmed">31194870</ArticleId></ArticleIdList></Reference><Reference><Citation>Weerasinghe SVW, Wambua M, and Pflum MKH (2010) A histone deacetylase-dependent screen in yeast, Bioorganic &amp; Medicinal Chemistry 18, 7586&#x2013;7592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033752</ArticleId><ArticleId IdType="pubmed">20863708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein BE, Tong JK, and Schreiber SL (2000) Genomewide studies of histone deacetylase function in yeast, Proceedings of the National Academy of Sciences 97, 13708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17640</ArticleId><ArticleId IdType="pubmed">11095743</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossaert E, Pollari E, Jaspers T, Van Helleputte L, Jarpe M, Van Damme P, De Bock K, Moisse M, and Van Den Bosch L (2019) Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model, Acta Neuropathologica Communications 7, 107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6612190</ArticleId><ArticleId IdType="pubmed">31277703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-C, Kumar MS, Ramesh N, Anderson EN, Nguyen AT, Kim B, Cheung S, McDonough JA, Skarnes WC, Lopez-Gonzalez R, Landers JE, Fawzi NL, Mackenzie IRA, Lee EB, Nickerson JA, Grunwald D, Pandey UB, and Bosco DA (2021) Interactions between ALS-linked FUS and nucleoporins are associated with defects in the nucleocytoplasmic transport pathway, Nature Neuroscience 24, 1077&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8832378</ArticleId><ArticleId IdType="pubmed">34059832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>